Find research datasets worth reusing

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

ClinicalTrials.gov study NCT00200967. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (

ClinicalTrials.gov study NCT00565266. IPD Sharing: Not stated. Countries: 1. Publications: 6.

closedIPD-NOFeb 2026View details →

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

ClinicalTrials.gov study NCT02330276. IPD Sharing: NO. Countries: 1. Publications: 1.

Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)

ClinicalTrials.gov study NCT00495157. IPD Sharing: Not stated. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of

ClinicalTrials.gov study NCT03585270. IPD Sharing: NO. Countries: 15. Publications: 2.

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

ClinicalTrials.gov study NCT03937817. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

Transforming Research and Clinical Knowledge in TBI Pilot

ClinicalTrials.gov study NCT01565551. IPD Sharing: Not stated. Countries: 1. Publications: 28.

publicAug 2024View details →

dryad36/100

Implementing virtual workspaces for clinical research at an academic health center: A case report

Open the record for dataset details and reuse information.

opencc-zeroOct 2020View details →

The clinical impact of high-profile animal-based research reported in the UK national press: a detailed discussion of articles from 1995, and full search results from the Nexis database

Objectives: We evaluated animal-based biomedical 'breakthroughs' reported in the UK national press in 1995 (25 years prior to the conclusion of this study). Based on evidence of over-speculative reporting of biomedical research in other areas (e.g. press releases and scientific papers), we specifically examined animal research in the media, asking, "In a given year, what proportion of animal research 'breakthroughs' published in the UK national press had translated, more than 20 years later, to approved interventions?" Methods: We searched the Nexis media database (LexisNexis.com) for animal-based biomedical reports in the UK national press. The only restrictions were that the intervention should be specific, such as a named drug, gene, biomedical pathway, to facilitate follow-up, and that there should be claims of some clinical promise. Main Outcome Measures: Were any interventions approved for human use? If so, when and by which agency? If not, why, and how far did development proceed? Were any other, directly related interventions approved? Did any of the reports over-state human relevance? Results: Over-speculation and exaggeration of human relevance was evident in all the articles examined. Of 27 unique published 'breakthroughs', only one had clearly resulted in human benefit. Twenty were classified as failures, three were inconclusive, and three were partially successful. Conclusions: The results of animal-based pre-clinical research studies are commonly over-stated in media reports, to prematurely imply often-imminent 'breakthroughs' relevant to human medicine.

opencc-zeroDec 2019View details →

Study design factors influencing patients' willingness to participate in clinical research: a randomised vignette-based study

Background: High patient participation in clinical research reduces selection bias, and ensures the generalisability of study findings. We explored study-related factors that may influence patients' willingness to participate in research. Methods: We submitted by mail two vignettes that described clinical research studies – a drug trial, and a diagnostic study – to patients recently discharged from hospital, and assessed Background: High patient participation in clinical research reduces selection bias, and ensures the generalisability of study findings. We explored study-related factors that may influence patients' willingness to participate in research. Methods: We submitted by mail two vignettes that described clinical research studies – a drug trial, and a diagnostic study – to patients recently discharged from hospital, and assessed their willingness to participate. We used a factorial design to randomly allocate three study attributes per vignette: in the drug trial, presumed superiority of new drug versus equipoise, public versus industry funding, and random versus non-random treatment allocation; in the diagnostic study, common versus rare disease, genetic versus protein analysis, and automatic reporting of results versus reporting on demand. Results: Of 2600 patients contacted, 1140 (44%) participated. Globally, willingness to participate in a drug trial was lower than in a diagnostic study (44.8% vs. 76.2%; P <0.001). In the drug trial, participation was significantly higher when the new drug was presented as presumably better than the old (vs. equipoise) and when the study was funded by public sources (vs. industry), but was not affected by the allocation method. None of the factors tested in the diagnostic study was associated with participation. Conclusions: Patients were more likely to participate in a hypothetical observational diagnostic study than in a hypothetical drug trial. Participation in the trial was lower when clinical equipoise was expressed, and when the trial was funded by industry. These results suggest that some features of study design can influence participation.their willingness to participate. We used a factorial design to randomly allocate three study attributes per vignette: in the drug trial, presumed superiority of new drug versus equipoise, public versus industry funding, and random versus non-random treatment allocation; in the diagnostic study, common versus rare disease, genetic versus protein analysis, and automatic reporting of results versus reporting on demand.

opencc-zeroDec 2019View details →

Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? an analysis of opinion papers

Objectives Despite decades of research using animals to develop pharmaceutical treatments for stroke patients, few therapeutic options exist. The vast majority of interventions successful in preclinical animal studies have turned out to have no efficacy in humans, or to be harmful to humans. In view of this we explore whether there is evidence of a move away from animal models in this field. Methods We used an innovative methodology, the analysis of opinion papers. Although we took a systematic approach to literature searching and data extraction, this is not a systematic review because the study involves the synthesis of opinions, not research evidence. Data were extracted from retrieved papers in chronological order and analysed qualitatively and descriptively. Results Eighty eligible papers, published between 1979 and 2018, were identified. Most authors were from academic departments of neurology, neuroscience or stroke research. Authors agreed that translational stroke research was in crisis. They held diverse views about the causes of this crisis, most of which did not fundamentally challenge the use of animal models. Some, however, attributed the translational crisis to animal-human species differences and one to a lack of human in vitro models. Most of the proposed solutions involved fine-tuning animal models but authors disagreed about whether such modifications would improve translation. A minority suggested using human in vitro methods alongside animal models. One proposed focusing only on human based in vitro methods. Conclusion Despite recognising that animal models have been unsuccessful in the field of stroke, most researchers exhibited a strong resistance to relinquishing them. Nevertheless there is an emerging challenge to the use of animal models, in the form of human focused in vitro approaches. For the sake of stroke patients there is an urgent need to revitalise translational stroke research and explore the evidence for these new approaches.

zenodo32/100

Dataset for research: "MTA and Koedam Score Contributes to Cognitive Impairment in Probable Alzheimer, Vascular and Mixed Dementia: A Memory Clinic Study in Indonesia"

This is a dataset for research : "MTA and Koedam Score Contributes to Cognitive Impairment in Probable Alzheimer, Vascular and Mixed Dementia: A Memory Clinic Study in Indonesia" <h1>Abstract</h1> Background. Medial Temporal Atrophy (MTA) and Parietal Atrophy (Koedam score) have been used in clinical practice to help the diagnosis of Alzheimer’s disease. However, the role of this brain imaging marker in early detection of other type of dementia remains elusive. The study aims to investigate the association between MTA and Koedam scores with the cognitive function in dementia patients (Alzheimer, vascular and mixed dementia). Method This was a cross-sectional study using data from a Memory Clinic in Dr. Sardjito General Hospital Yogyakarta, Indonesia. The data was collected from January 2020 until December 2022. We collected the data regarding demographic and clinical characteristics, including head MRI data and Montreal Cognitive Assessment (MoCA) score. The cut-off points of MTA score and Koedam score were determined by using Receiver Operating Curve (ROC) and Youden Index. Multivariate analysis was performed to investigate variables which were associated with the cognitive function.  Result From 61 dementia patients, 22.95% was probable Alzheimer’s disease, 59.01% was vascular dementia, and 18.03% was mixed dementia. Correlation test showed that MTA and Koedam score were negatively associated with Montreal Cognitive Assessment-Indonesian Version (MoCA-INA) score. A bivariate analysis supports the findings that patients with combination of MTA score ≥3 and Koedam score ≥2 was more likely to have poor cognitive function (OR= 11.33; p<0.05). Multivariate analysis showed higher MTA (≥3) and Koedam (≥2) scores were associated with poor cognitive function in dementia patients (OR= 13.54, 95% CI= 1.77-103.43, p=0.01 and OR= 5.52, 95% CI= 1.08-28.19, p=0.04) Conclusion Higher MTA and Koedam score contribute to worse cognitive function in any type of dementia patients. Keywords. Imaging Marker, Medial Temporal Atrophy (MTA), Koedam Score, Cognitive Function, Dementia

opencc-by-4.0Dec 2023View details →

opencc-zeroJan 2024View details →

Climate footprint of industry-sponsored clinical research: An analysis of a phase-1 randomized clinical study and discussion of opportunities to reduce its impact

Objective: To calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from a phase-1 clinical study Design: Retrospective analysis. Data source: Internal data held by Janssen Pharmaceuticals Studies included: Janssen-sponsored TMC114FD1HTX1002 study conducted between 2019-2021 Main outcome: measure CO2 equivalents for trial activities calculated according to IPCC 2021 impact assessment methodology Results: The CO2-eq emissions generated by the trial was 17.65 tonnes. This is equivalent to the emissions generated by driving the average petrol-fueled family car 71,004km or roughly 1.8 times around the circumference of the Earth. Commuting to the clinical site by the study patients generated the most emissions (5,419kg, 31% of overall emissions), followed by trial site utilities (2,725kg, 16% of overall emissions), and Janssen site staff travel (2,560kg, 15% of overall emissions). In total, the movement of people (patient travel, Janssen site staff travel, and trial site staff travel) accounted for 8,914kg or 51% of overall trial emissions. Conclusions: Opportunities exist to reduce many of the largest contributors to the clinical trial's CO2-eq emissions. The largest contributor was patient travel (31%) and combined with sponsor (15%) and site staff (5%) travel, the movement of people was responsible for 51% of CO2-eq emissions. Decentralized trial models which seek to bring clinical trial operations closer to the patient offer opportunities to reduce patient travel. The electrification of sponsor vehicle fleets and society's transition towards electric vehicles may result in further reductions.

zenodo32/100

Tumor multi-omics profiles and clinical information employed in TMO-Net research

This dataset includes tumor multi-omics profiles used in TMO-Net research. The preprocessed TCGA pan-cancer multi-omics were employed during pre-training stage of TMO-Net. The metabric multi-omics dataset, metastatistic tumor multi-omics dataset, PDX cell line multi-omics dataset, GDSC cell line multi-omice dataset, CPTAC cancer multi-omics dataset and metastatic dataset were used for downstream tasks and analysis.

opencc-by-4.0Apr 2024View details →

controlledIPD-YESFeb 2026View details →

International CDKL5 Clinical Research Network

ClinicalTrials.gov study NCT05558371. IPD Sharing: YES. Countries: 2. Publications: 9.

Understanding Patient Engagement Trends in TBI Clinical Research

ClinicalTrials.gov study NCT06288698. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

Patient Perspectives in Mantle Cell Lymphoma Clinical Research

ClinicalTrials.gov study NCT06049472. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

Clinical Research of Intravenous Thrombolysis for Ischemic Stroke in Northeast of China

ClinicalTrials.gov study NCT05028868. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

Chromosome 18 Clinical Research Center

ClinicalTrials.gov study NCT00227253. IPD Sharing: Not stated. Countries: 1. Publications: 24.

Clinical Research on the Efficacy of Bosinji on Herniated Intervertebral Disc of Lumbar Spine

ClinicalTrials.gov study NCT03386149. IPD Sharing: Not stated. Countries: 1. Publications: 2.